Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors

Nicola E. Annels, Guy R. Simpson, Mick Denyer, Mehreen Arif, Matt Coffey, Alan Melcher, Kevin Harrington, Richard Vile, Hardev Pandha

Research output: Contribution to journalArticlepeer-review

Abstract

Immunotherapy in prostate cancer is limited because of a lack of immune cells within the tumor. Annels et al. used oncolytic viruses to recruit immune cells into the tumor and showed that in combination with checkpoint inhibitors, which take the brake off of the immune system, established tumors were rejected.

Original languageEnglish (US)
Pages (from-to)434-446
Number of pages13
JournalMolecular Therapy - Oncolytics
Volume20
DOIs
StatePublished - Mar 26 2021

Keywords

  • Immunotherapy resistance
  • Oncolytic virus
  • Prostate cancer

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors'. Together they form a unique fingerprint.

Cite this